EMA, FDA Get Together On Drugs Eligible For PRIME And Breakthrough Designation
This article was originally published in SRA
Executive Summary
The European Medicines Agency and the US Food and Drug Administration are looking at ways to exchange notes on drugs that become eligible for their respective schemes on speeding access to new innovative medicines ie, Priority Medicines (PRIME) in the EU and breakthrough therapy designation in the US.